Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 3526
- Registration Number
- NCT00074581
- Locations
- 🇺🇸
Fenway Community Health Ctr. CRS, Boston, Massachusetts, United States
🇧🇼Gaborone CRS, Gaborone, Botswana
🇧🇷Hospital Geral de Nova Iguaçu CRS (HGNI CRS), Nova Iguacu, Rio De Janeiro, Brazil
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
- Conditions
- First Posted Date
- 2003-02-05
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 345
- Registration Number
- NCT00053638
- Locations
- 🇺🇸
GSK Investigational Site, Green Bay, Wisconsin, United States
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
- Conditions
- Interventions
Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 775
- Registration Number
- NCT00050895
- Locations
- 🇺🇸
IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Conditions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT00038532
- Locations
- 🇨🇦
Toronto General Hospital Division of The University Health Network, Toronto, Ontario, Canada
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Diversified Medical Practices, P.A., Houston, Texas, United States
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
- Conditions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2006-07-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 40
- Registration Number
- NCT00038220
- Locations
- 🇺🇸
Aaron Diamond AIDS Research Center - Rockefeller University, New York, New York, United States
Increasing HAART-Induced Immune Restoration With Cyclosporine
- Conditions
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2015-03-09
- Target Recruit Count
- 40
- Registration Number
- NCT00031070
- Locations
- 🇺🇸
Univ of Texas, Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Washington Univ (St. Louis), St. Louis, Missouri, United States
🇺🇸University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
- Conditions
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 250
- Registration Number
- NCT00028327
- Locations
- 🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
🇺🇸Washington Univ School of Medicine, St Louis, Missouri, United States
TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 20
- Registration Number
- NCT00023413
- Locations
- 🇺🇸
Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.